Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 22, 2006

Esprit Grants Depomed $10M License Fee

  • Esprit paid Depomed a $10 million license fee payment due under the parties' license agreement for ProQuin® XR, a treatment for uncomplicated urinary tract infections. ProQuin XR, an extended release formulation of the antibiotic ciprofloxacin, was developed by Depomed and exclusively licensed in the U.S. to Esprit.

    In addition, Depomed and Esprit have agreed to commence discussions toward a mutually agreeable restructuring of their license agreement after the new year. In the meantime, the existing agreement will remain in effect.
    Depomed also agreed to withdraw the notice of breach and demand for arbitration related to the license agreement.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »